Investors worldwide are looking to see if the European countries will follow in the footsteps of the United States and Canada with legalizing cannabinoid substances for recreational and medical use. It’s apparent that significant pressure is mounted on the EU governments to introduce new regulations, especially ones that provide access to cannabinoid substances for medical patients. Considering the large unmet demand for such medicines there is a great opportunity for suppliers to expand their business operations and potentially enter the huge European market.
This 44-page report showcases our findings and analysis of the medicinal cannabis market in Germany.
Download our showcase Bearstone Insights report to find out:
- What are the current legal regulations in Germany?
- Should further liberalisation be expected?
- Who are the key market players?
- What are the main red flags for investors?
- What do the industry experts have to say about the future of the sector?
The information contained in this document is based on available sources and analysis at the time of writing and is of a general nature only. It is not intended as advice regarding any individual situation and cannot be relied upon as such. Where human sources are quoted, the views expressed are those of the sources only, and should not be construed as being the views of Bearstone Global. Statements concerning financial, regulatory, or legal matters are general observations based solely on our experience and may not be relied upon as advice in those areas, which we are not authorised to provide. All such matters should be reviewed with appropriately qualified financial, regulatory, or legal advisers. In no circumstances will Bearstone Global be liable for any loss or damage arising from decisions made or actions taken in reliance on the information contained herein.